JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Johnson & Johnson (JNJ) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has strong fundamentals, positive analyst ratings, and a solid pipeline, the recent price decline, insider selling, and lack of strong trading signals suggest waiting for a better entry point.
The stock's MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 31.796, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is near its support level of 229.487, with resistance at 240.183. Recent price action shows a -2.48% regular market decline, suggesting short-term weakness.
Analysts have upgraded the stock with increased price targets, citing strong new drug momentum and double-digit revenue growth potential.
Congress trading data shows a significant purchase transaction in the last 90 days, indicating confidence from influential figures.
The company's strong pipeline and recent product approvals (e.g., Icotyde) support long-term growth.
Insider selling has increased significantly by 159.20% over the last month, which may indicate a lack of confidence from company insiders.
The broader pharmaceutical sector faces headwinds due to proposed Medicare drug price negotiations.
Recent market performance shows a -2.48% decline, reflecting short-term bearish sentiment.
No financial data available for the latest quarter. However, analysts highlight strong Q1 earnings, driven by Tremfya uptake, successful Icotyde adoption, and steady MedTech performance.
Analysts are broadly positive on JNJ, with multiple upgrades and price target increases. Current price targets range from $250 to $283, with an average target of approximately $263, indicating upside potential from the current price of $228.63.
